A short report on highlights of world-wide development of RIX4414: an European experience.
Vesikari
T
T
University of Tampere, Medical School/FM3, Vaccine Research Center, University of Tampere, 33014 Tampere, Finland. timo.vesikari@uta.fi
Karvonen
A
A
Puustinen
L
L
Szakal
E D
ED
Zeng
S-Q
SQ
Delem
A
A
De Vos
B
B
D000284:Administration, Oral; D000914:Antibodies, Viral / Q000097:blood; D001530:Belgium; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D005243:Feces / Q000821:virology; D005387:Finland; D005759:Gastroenteritis / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007223:Infant; D016032:Randomized Controlled Trials as Topic; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D017201:Virus Shedding
D000914:Antibodies, Viral; D007070:Immunoglobulin A; C492457:RIX4414 vaccine; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated